The revolutionary arthritis drug from SK chemicals, entering the third stage of clinical testing, SKI306X; a hard to cure arthritis drug developed by SK chemicals. For the first time in Korea, SKI306X was developed by conjoining Eastern and Western medical concepts. It overcame side effects of anti-inflammatory analgesia in pre-clinical testing. It is a revolutionary drug curing arthritis fundamentally through the prevention of destruction, protection and regeneration of arthrosis which have been considered impossible by current medical practices. Arthritis can be divide into osteoarthritis and rheumatoid arthritis. There is no drug for both so symptomatic treatment is performed using anti-inflammatory analgesia. Currently, 12 % of the people in the world or 70 % of people over age 60 suffer from osteoarthritis. Chronic diseases will increase due to aging and environmental contamination, so the arthritis market is expected to increase rapidly. The Central Research Institute of SK chemicals has tried to find a new concept arthritis drug based on Eastern medication logic since 1994 and has tried to confirm the idea based on the scientific experiments of Western medication. In Eastern medication, arthritis results from wind, cold and humidity. It can be cured if those causes are removed. Based on this logic, more than 1,000 natural products have been researched and eventually led to the development of SKI306X. Pre-clinical experiments showed that it effects the suppression of arthritis pathogenesis, protection and quick regeneration of arthrosis. Furthermore, during second stage clinical testing (Orthopedic Surgery in Choongang Univ. Hospital and Ewha Univ. Hospital), the drug showed it has an efficacy as high as 94 % in treatment and effect. Under continuous use for 4 weeks it did not show any side effects on the stomach or liver which used to be observed in existing drugs. It identifies SKI306X as a potential drug for arthritis overcoming serious stomach problems or side effects on the whole body due to anti-inflammatory analgesia used for symptomatic treatment. SKI306X acquired clinical conditioned drug approval from the Ministry of Health and Welfare in 1997, and the second stage of clinical tests was successfully completed in 1999. Currently, patients for the third stage of clinical experiment are being researched. Its commercialization is expected by early 2001. It will create a new market as well as overtake a large portion of the domestic arthritis drug market reaching $167 million dollars due to its efficacy as a basic medication for all arthritis patients. Furthermore, it will be introduced in the international arthritis market reaching $30 billion dollars through an overseas licensing.